Intellia Therapeutics Reports Positive Phase 3 HAELO Data for lonvo-z in HAE and Resumes Nex-z ATTR Phase 3 Enrollment

August 9, 2026

Intellia Therapeutics USA

Overview

Intellia Therapeutics announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), published in the New England Journal of Medicine. The company anticipates FDA Biologics License Application (BLA) acceptance for lonvo-z in H2 2026, targeting a H1 2027 U.S. launch. Furthermore, enrollment has restarted for the Phase 3 clinical trial of nex-z for ATTR, backed by new genomic analyses that reinforce its safety profile and potential for clinically meaningful outcomes.

In Depth

Key Findings

Intellia Therapeutics reported significant advancements in its CRISPR gene editing pipeline during its Q2 2026 financial and business update. Notably, positive Phase 3 HAELO clinical data for lonvo-z, targeting hereditary angioedema (HAE), were announced, with the results published in the prestigious New England Journal of Medicine and presented at EAACI.

Technical and Clinical Details

Lonvo-z, an in vivo CRISPR-based gene editing therapy, demonstrated compelling efficacy and safety in the HAELO trial, validating its potential as a transformative treatment for HAE. Following these results, Intellia projects FDA acceptance of the Biologics License Application (BLA) for lonvo-z in the second half of 2026, with a U.S. launch anticipated in the first half of 2027. Concurrently, enrollment for the Phase 3 clinical trial of nex-z, designed to treat ATTR (transthyretin amyloidosis), has resumed. This decision follows new genomic analyses that have further strengthened the therapy’s safety profile and underscored its potential to deliver clinically meaningful outcomes for patients suffering from this debilitating condition.

Background and Industry Context

Intellia Therapeutics operates as a clinical-stage biopharmaceutical company leveraging its proprietary CRISPR gene editing platform to develop novel treatments for severe diseases with high unmet medical needs. The company’s strategy encompasses both in vivo (direct in-body editing) and ex vivo (editing outside the body and re-infusing) approaches, aiming to offer curative solutions for a broad range of genetic disorders. The advancements with lonvo-z and nex-z highlight the growing maturity and therapeutic potential of CRISPR technology within the biopharmaceutical landscape, moving from foundational research to late-stage clinical development and commercialization.

Strategic Significance and Outlook

The impending BLA acceptance and commercial launch of lonvo-z, coupled with the recommencement of the nex-z Phase 3 trial, signify critical milestones for Intellia Therapeutics and the broader gene editing field. These developments not only validate Intellia’s scientific and clinical capabilities but also promise to expand patient access to potentially life-changing genetic therapies. The company remains committed to advancing its robust pipeline, reinforcing its position at the forefront of precision medicine and contributing to a future where genetic diseases can be effectively treated or cured through innovative gene editing approaches.

Source: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-second-quarter-2026-financial

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.